Comparing blood thinners for people with antiphospholipid syndrome
Part of Immune system & allergy clinical trials.
This study compares two types of blood thinners (vitamin K antagonists) in people with antiphospholipid syndrome, a condition where the immune system attacks healthy cells and increases blood clot risk. The goal is to see if one is better at preventing future blood clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have antiphospholipid syndrome (APS), a condition that increases your risk of blood clots.
- You are currently being treated with a vitamin K antagonist, such as warfarin (Coumadin).
- You are 18 years or older.
- You have had a medical exam and are willing to provide data for research.
- You do not need to be pregnant or planning to become pregnant (effective contraception is required if you can have children).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study keeps an international registry of people with antiphospholipid syndrome (APS) who are taking direct oral blood thinners. It may help doctors better understand how APS patients do over time and improve future care, even if you’re not asked to change treatment.
This study tests whether it is safe to stop taking blood thinners (vitamin K antagonists) if the antiphospholipid antibodies that caused your condition have been gone for at least a year. If you qualify, stopping treatment might reduce your risk of bleeding and improve your quality of life.
This study keeps a registry to follow people with antiphospholipid syndrome (APS) who have had arterial blood clots (like stroke). It collects information about the treatment approach your clinician chooses to see how different antithrombotic regimens may perform and be tolerated.
This study is for children who have antiphospholipid syndrome (APS) and a history of blood vessel clots. Researchers want to learn more about APS in pediatric patients who have specific blood test signs and clot history.
This study compares two types of blood thinners (DOACs like rivaroxaban or apixaban, and vitamin K blockers like warfarin) in people with antiphospholipid syndrome who had a vein clot. The goal is to see which one works better at preventing future clots without causing more bleeding.
This study looks at how well blood thinners prevent blood clots from coming back in people with antiphospholipid syndrome (APS) who are considered low risk. It compares two types of medicines: direct oral anticoagulants (DOACs) and vitamin K antagonists.
Hear when a new Antiphospholipid Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.